# KALV — KalVista Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** KALV  
**Sources:** 15  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-kalv-kalvista-pharmaceuticals-inc-catalysts-narrative-ri-10390

---

## Important framing: KALV is no longer a publicly traded asset (as of 2026‑10‑31)

The dominant fact to anchor on is that **KalVista Pharmaceuticals ceased to be a public company on June 11, 2026**, when Chiesi Group completed its takeover. KALV stopped trading on the Nasdaq Global Market as a result of the merger, and outstanding shares were cancelled and converted into the right to receive $27.00 per share in cash [[1]](https://www.stocktitan.net/sec-filings/KALV/8-k-kal-vista-pharmaceuticals-inc-reports-material-event-3dbf427f1884.html), [[2]](https://www.tipranks.com/news/company-announcements/chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals), [[3]](https://www.chiesi.com/en/media-hub/press-release/chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals.html). "Researching KALV as a publicly traded asset as of October 31, 2026" therefore means reviewing the terms and outcome of the acquisition that removed it from the public markets.

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-kalv-kalvista-pharmaceuticals-inc-catalysts-narrative-ri-10390 (free to sign up)._